PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: The AtheroGene Study

Journal of Lipid Research

Volumn 50, Issue 4, 2009, Pages 723-729

  Schlitt, Axel ^a   Blankenberg, Stefan ^b   Bickel, Christoph ^c   Lackner, Karl J ^b   Heine, Gunnar H ^d   Buerke, Michael ^a   Werdan, Karl ^a   Maegdefessel, Lars ^a   Raaz, Uwe ^a   Rupprecht, Hans J ^e   Munzel, Thomas ^b   Jiang, Xian Cheng ^f  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Deutsche Bundeswehr   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e GPR Clinic   (Germany)

^f STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Atherosclerosis; Lipid transfer proteins

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL; PLTP PROTEIN, HUMAN;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CASE CONTROL STUDY; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; RISK FACTOR;

AGED; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHOSPHOLIPID TRANSFER PROTEINS; PROGNOSIS; RISK FACTORS;

EID: 67449123466     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800414-JLR200     Document Type: Article

References (42)

1. Williams, K. J., and I. Tabas. 1995. The response-to-retention hypothesis of early atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15: 551-561.
2. Witztum, J. L., and D. Steinberg. 1991. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88: 1785-1792.
3. Nievelstein, P. F., A. M. Fogelman, G. Mottino, and J. S. Frank. 1991. Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein. Arterioscler. Thromb. 11: 1795-1805.
4. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362: 801-808.
5. Maron, D. J., S. Fazio, and M. F. Linton. 2000. Current perspectives on statins. Circulation. 101: 207-213.
6. Rosenson, R. S., and C. C. Tangney. 1998. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 279: 1643-1650.
7. Libby, P., W. Sasiela. 2006. Plaque stabilization: Can we turn theory into evidence? Am. J. Cardiol. 98: 26-33.
8. Nicholls, S. J., E. M. Tuzcu, I. Sipahi, A. W. Grasso, P. Schoenhagen, T. Hu, K. Wolski, T. Crowe, M. Y. Desai, S. L. Hazen, et al. 2007. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 297: 499-508.
9. Silber, S., P. Albertsson, F. F. Avilés, P. G. Camici, A. Colombo, C. Hamm, E. Jørgensen, J. Marco, J. E. Nordrehaug, W. Ruzyllo, P. Urban, G. W. Stone, and W. Wijns; Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. 2006. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur. Heart J. 26: 804-847.
10. Cannon, C. P., E. Braunwald, C. H. McCabe, D. J. Rader, J. L. Rouleau, R. Belder, S. V. Joyal, K. A. Hill, M. A. Pfeffer, and A. M. Skene. 2004. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350: 1495-1504.
11. de Lemos, J. A., M. A. Blazing, S. D. Wiviott, E. F. Lewis, K. A. Fox, H. D. White, J. L. Rouleau, T. R. Pedersen, L. H. Gardner, R. Mukherjee, et al. 2004. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 292: 1307-1316.
12. LaRosa, J. C., S. M. Grundy, D. D. Waters, C. Shear, P. Barter, J. C. Fruchart, A. M. Gotto, H. Greten, J. J. Kastelein, J. Shepherd, et al. 2005. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352: 1425-1435.
13. Pedersen, T. R., O. Faergeman, J. J. Kastelein, A. G. Olsson, M. J. Tikkanen, I. Holme, M. L. Larsen, F. S. Bendiksen, C. Lindahl, M. Szarek, et al. 2005. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 294: 2437-2445.
14. Tall, A. R., S. Krumholz, T. Olivecrona, and R. J. Deckelbaum. 1985. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J. Lipid Res. 26: 842-851.
15. Tu, A. Y., H. I. Nishida, and T. Nishida. 1993. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J. Biol. Chem. 268: 23098-23105.
16. Huuskonen, J., M. Ekstrom, E. Tahvanainen, A. Vainio, J. Metso, P. Pussinen, C. Ehnholm, V. M. Olkkonen, and M. Jauhiainen. 2000. Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid transfer activity. Atherosclerosis. 151: 451-461.
17. Oka, T., T. Kujiraoka, M. Ito, T. Egashira, S. Takahashi, M. N. Nanjee, N. E. Miller, J. Metso, V. M. Olkkonen, C. Ehnholm, et al. 2000. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J. Lipid Res. 41: 1651-1657.
18. Karkkainen, M., T. Oka, V. M. Olkkonen, J. Metso, H. Hattori, M. Jauhiainen, and C. Ehnholm. 2002. Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). J. Biol. Chem. 277: 15413-15418.
19. Jiang, X. C., O. L. Francone, C. Bruce, R. Milne, J. Mar, A. Walsh, J. L. Breslow, and A. R. Tall. 1996. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J. Clin. Invest. 98: 2373-2380.
20. Foger, B., S. Santamarina-Fojo, R. D. Shamburek, C. L. Parrot, G. D. Talley, and H. B. Brewer, Jr. 1997. Plasma phospholipid transfer protein: adenovirusmediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL. J. Biol. Chem. 272: 27393-27400.
21. Ehnholm, S., K. W. van Dijk, B. van't Hof, A. van der Zee, V. M. Olkkonen, M. Jauhiainen, M. Hofker, L. Havekes, and C. Ehnholm. 1998. Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice. J. Lipid Res. 39: 1248-1253.
22. Jiang, X. C., S. Qin, L. Min, M. Schneider, A. R. Tall, and L. Lagrost. 2001. Phospholipid transfer protein (PLTP) deficiency represents an anti-oxidant state in mice. Circulation. 104: II-232.
23. Qin, S., A. R. Tall, and X. C. Jiang. 2001. Phospholipid transfer protein deficiency reduces atherogenesis by inhibited LDL oxidation in LDL receptor knock out mice on western type diet. Circulation. 104: II-329.
24. Jiang, X. C., S. Qin, C. Qiao, K. Kawano, M. Lin, A. Skold, X. Xiao, and A. R. Tall. 2001. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat. Med. 7: 847-852.
25. Jiang, X. C., A. R. Tall, S. Qin, M. Lin, M. Schneider, F. Lalanne, V. Deckert, C. Desrumaux, A. Athias, J. L. Witztum, et al. 2002. Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J. Biol. Chem. 277: 31850-31856.
26. van Haperen, R., A. van Tol, T. van Gent, L. Scheek, P. Visser, A. van der Kamp, F. Grosveld, and R. de Crom. 2002. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J. Biol. Chem. 277: 48938-48943.
27. Lie, J., R. de Crom, T. van Gent, R. van Haperen, L. Scheek, I. Lankhuizen, and A. van Tol. 2002. Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. J. Lipid Res. 43: 1875-1880.
28. Schlitt, A., C. Bickel, P. Thumma, S. Blankenberg, H. J. Rupprecht, J. Meyer, and X. C. Jiang. 2003. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 23: 1857-1862.
29. Jauhiainen, M., J. Metso, R. Pahlman, S. Blomqvist, A. van Tol, and C. Ehnholm. 1993. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J. Biol. Chem. 268: 4032-4036.
30. Schgoer, W., T. Mueller, M. Jauhiainen, A. Wehinger, R. Gander, I. Tancevski, K. Salzmann, P. Eller, A. Ritsch, M. Haltmayer, et al. 2008. Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis. 196: 219-226.
31. Schlitt, A., G. H. Heine, X. C. Jiang, M. Messow, S. Blankenberg, H. J. Rupprecht, C. Ulrich, M. Buerke, K. Werdan, K. J. Lackner, et al. 2007. Phospholipid transfer protein (PLTP) in hemodialysis patients. Am. J. Nephrol. 27: 138-143.
32. Takemoto, M., and J. K. Liao. 2001. Pleiotropic effects of 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21: 1712-1719.
33. Yan, D., M. Navab, C. Bruce, A. M. Fogelman, and X. C. Jiang. 2004. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. J. Lipid Res. 45: 1852-1858.
34. Schlitt, A., J. Liu, D. Yan, M. Mondragon-Escorpizo, A. J. Norin, and X. C. Jiang. 2005. Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. Biochim. Biophys. Acta. 1733: 187-191.
35. Liu, R., J. Iqbal, C. Yeang, D. Q. Wang, M. M. Hussain, and X. C. Jiang. 2007. Phospholipid transfer protein-deficient mice absorb less cholesterol. Arterioscler. Thromb. Vasc. Biol. 27: 2014-2021.
36. Yang, X. P., D. Yan, C. Qiao, R. J. Liu, J. G. Chen, J. Li, M. Schneider, L. Lagrost, X. Xiao, and X. C. Jiang. 2003. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler. Thromb. Vasc. Biol. 23: 1601-1607.
37. Dallinga-Thie, G. M., A. van Tol, H. Hattori, P. C. Rensen, and E. J. Sijbrands. 2006. Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E? Diabetes. 55: 1491-1496.
38. Lagrost, L., A. Athias, N. Lemort, J. L. Richard, C. Desrumaux, L. Chatenet-Duchene, M. Courtois, M. Farnier, B. Jacotot, S. Braschi, et al. 1999. Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin. Atherosclerosis. 143: 415-425.
39. Cheung, M. C., G. Wolfbauer, H. Kennedy, B. G. Brown, and J. J. Albers. 2001. Plasma phospholipid transfer protein activity in patients with low HDL and cardiovascular disease treated with simvastatin and niacin. Biochim. Biophys. Acta. 1537: 117-124.
40. Vuletic, S., R. G. Riekse, S. M. Marcovina, E. R. Peskind, W. R. Hazzard, and J. J. Albers. 2006. Statins of different brain penetrability differentially affect CSF PLTP activity. Dement. Geriatr. Cogn. Disord. 22: 392-398.
41. Qin, S., K. Kawano, C. Bruce, M. Lin, C. Bisgaier, A. R. Tall, and X. Jiang. 2000. Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. J. Lipid Res. 41: 269-276.
42. Sviridov, D., A. Hoang, E. Ooi, G. Watts, P. H. Barrett, and P. Nestel. 2008. Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis. 197: 732-739.